LUND, Sweden (Nov. 6, 2023) – TFS HealthScience, a global contract research organization (CRO), announces its strategic investment in Medidata Detect, a comprehensive data surveillance and risk monitoring solution that improves data quality and promotes patient safety in clinical trials. TFS stands as the first CRO to adopt Medidata Detect technology for its clients.
Medidata Detect will help data managers and clinical operations teams improve patient safety, data quality oversight, and risk management. By analyzing and harmonizing data from many sources in a single location and identifying patterns and discrepancies, this solution offers a complete view of clinical trials and drives efficient workflows – allowing TFS to better focus on patients and clients.
“In spearheading our adoption of Medidata Detect, we’re not only reinforcing our commitment to data quality and patient safety, but we’re also embracing a pivotal enhancement to our existing technology stack,” said Michael Mendoza, TFS Executive Director of eClinical Technology and Biometrics. “Our partnership with Medidata now extends beyond the realms of Rave® EDC, CTMS, and eTMF, illustrating a significant step in our long-term strategy to advance clinical trial efficiency through innovation.”
“We are thrilled to be the first CRO implementing Medidata’s Detect platform, which addresses many data inefficiencies the industry experiences today,” said TFS Chief Executive Officer, Dr. Bassem Saleh. “Using a centralized data management system will enhance data quality, risk management, and decision-making, fast-tracking clinical trials for clients and the availability of drugs for patients.”
Detect identifies and addresses both known and unexpected risks in trials, prompting corrective actions that prevent study delays and submission failures. As a cornerstone of the risk-based quality management approach to clinical development, this innovative solution streamlines data management by eliminating breakpoints and will expand TFS HealthScience’s data access across platforms.
“At Medidata, we’re collaborating with our 2,300+ global customers to accelerate clinical trials by developing new, scalable data experiences that improve quality, maximize efficiency, and better support patients,” said Tom Doyle, Chief Technology Officer, Medidata. “Medidata Detect will give TFS HealthScience a competitive advantage with AI-driven insights and task automation that reduce the time to high-quality data and bring operational teams closer, eliminating redundancies and aligning processes across the organization.”
This partnership solidifies TFS as a leading and innovative clinical research organization focused on accelerating safety review cycles and helping biotechnology and pharmaceutical companies bring life-changing products, therapies, and medications to market as quickly as possible. “This integration showcases our dedication to leveraging cutting-edge technology for clinical excellence. It’s a testament to the proactive strides TFS is taking to grow technologically and further solidify our full partnership with Medidata,” highlighted Mendoza.
About TFS HealthScience
TFS HealthScience is a global Contract Research Organization (CRO) that supports biotechnology and pharmaceutical companies throughout their entire clinical development journey. In partnership with customers, we build solution-driven teams working for a healthier future. Bringing together more than 800 professionals, TFS delivers tailored clinical research services in more than 40 countries and supports customers with comprehensive solutions through two strong business models: Clinical Development Services (CDS), which provides full-service support at all stages of the clinical development process and Strategic Resourcing Solutions (SRS), which offers expert insourcing, targeted recruitment, and strategic workforce management solutions.
Detailed information about TFS and its business offerings can be obtained through www.tfscro.com.
Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. With over 20 years of groundbreaking technological innovation across more than 30,000 trials and 9 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across 2,100+ customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. The company is a wholly owned subsidiary of Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA), which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.
About Dassault Systèmes
Dassault Systèmes, the 3DEXPERIENCE® Company, is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers can redefine the creation, production and life-cycle-management processes of their offer and thus have a meaningful impact to make the world more sustainable. The beauty of the Experience Economy is that it is a human-centered economy for the benefit of all –consumers, patients and citizens. Dassault Systèmes brings value to more than 300,000 customers of all sizes, in all industries, in more than 150 countries. For more information, visit www.3ds.com.